论文部分内容阅读
应用双抗体夹心酶联免疫吸附法(ELISA)检测45例胃癌患者血清中可溶性FasL(sFasL)水平,并取30例健康献血员为对照。结果显示,胃癌患者术前血清sFasL为(15.24±1.25)μg/L,30例健康献血员sFasL病理为(4.21±1.13)μg/L。两组比较P<0.01。胃癌患者术前血清sFasL含量[(15.24±1.25)μg/L]显著高于术后(5.36±1.19)μg/L],P <0.01,且分期越高、分化程度越低、有淋巴结转移、肿瘤直径>3cm者,术前血清sFasL越高。提示胃癌患者血清中含有sFasL,且sFasL在胃癌免疫逃逸、反击机制中起重要作用;术前胃癌血清中sFasL水平可作为术后随访和判断预后的一个重要指标。
The levels of soluble FasL (sFasL) in serum of 45 patients with gastric cancer were detected by double antibody sandwich enzyme-linked immunosorbent assay (ELISA), and 30 healthy blood donors were taken as control. The results showed that the preoperative sFasL of gastric cancer patients was (15.24 ± 1.25) μg / L, and the pathological changes of sFasL in 30 healthy blood donors were (4.21 ± 1.13) μg / L. The two groups compared P <0.01. Preoperative serum sFasL level was significantly higher in gastric cancer patients (15.24 ± 1.25 μg / L vs 5.36 ± 1.19 μg / L postoperatively, P <0.01), and the higher the stage, the lower the degree of differentiation and lymph node metastasis, Tumor diameter> 3cm, preoperative serum sFasL higher. Suggesting that sFasL is present in the serum of patients with gastric cancer, and sFasL plays an important role in immune escape and counterattack mechanism of gastric cancer. The level of sFasL in preoperative gastric cancer serum can be used as an important index for follow-up and prognosis.